Decentralized & Hybrid Clinical Trials (DCTs)

Digital Tools and Platforms Required to Enable Regulatory Expectations for DCTs Digital Tools and Platforms Required to Enable Regulatory Expectations for DCTs Decentralized Clinical Trials (DCTs) have gained traction as a time-efficient and patient-centric method of conducting research. As regulatory agencies like the FDA and the EMA establish frameworks for DCTs, clinical research professionals must…

Read More “Digital Tools and Platforms Required to Enable Regulatory Expectations for DCTs” »

Digital Tools and Platforms Required to Enable Regulatory Expectations for DCTs As the clinical research ecosystem evolves, regulatory expectations for decentralized and hybrid clinical trials (DCTs) are increasingly in focus. The integration of digital tools and platforms is paramount for ensuring compliance with the guidelines set forth by regulatory authorities like the FDA, EMA, and…

Read More “Digital Tools and Platforms Required to Enable Regulatory Expectations for DCTs” »

Future Trends: Hybrid, Virtual and Platform-Enabled Regulatory Expectations for DCTs Decentralized Clinical Trials (DCTs) have emerged as a flexible approach to clinical research, leveraging advancements in technology to enhance patient participation and data collection. As a result, the regulatory landscape must adapt to accommodate these innovative methodologies. This article provides a step-by-step tutorial that highlights…

Read More “Future Trends: Hybrid, Virtual and Platform-Enabled Regulatory Expectations for DCTs” »

Global Implementation Models for Regulatory Expectations for DCTs Across US, EU and UK As the landscape of clinical trials continuously evolves, understanding the regulatory expectations for decentralized and hybrid clinical trials (DCTs) becomes crucial for clinical operations, regulatory affairs, and medical affairs professionals. This guide will provide a comprehensive, step-by-step tutorial on implementing DCTs in…

Read More “Global Implementation Models for Regulatory Expectations for DCTs Across US, EU and UK” »

Data Privacy, Security and Consent Considerations in Regulatory Expectations for DCTs Data Privacy, Security and Consent Considerations in Regulatory Expectations for DCTs Decentralized clinical trials (DCTs) are reshaping the landscape of clinical research, offering innovative approaches to patient recruitment, data collection, and study management. However, the transition to DCTs brings forth a set of challenges,…

Read More “Data Privacy, Security and Consent Considerations in Regulatory Expectations for DCTs” »

Training Sites, Nurses and Coordinators to Execute Regulatory Expectations for DCTs Training Sites, Nurses and Coordinators to Execute Regulatory Expectations for DCTs Understanding Decentralized Clinical Trials (DCTs) Decentralized clinical trials (DCTs) represent a paradigm shift in the execution of clinical research, wherein the traditional site-based model is replaced or supplemented by remote and patient-centric approaches….

Read More “Training Sites, Nurses and Coordinators to Execute Regulatory Expectations for DCTs” »

Vendor Oversight and Contracts for Technology-Heavy Regulatory Expectations for DCTs The rapid evolution of technology in clinical trials has led to the emergence of decentralized and hybrid clinical trials (DCTs), significantly impacting the regulatory landscape. As clinical professionals, understanding the implications of vendor oversight and contractual agreements while adhering to regulatory expectations is paramount. This…

Read More “Vendor Oversight and Contracts for Technology-Heavy Regulatory Expectations for DCTs” »

Vendor Oversight and Contracts for Technology-Heavy Regulatory Expectations for DCTs In recent years, decentralized clinical trials (DCTs) have emerged as a transformative approach to clinical research, leveraging technology to enhance patient access and data collection methodologies. Regulatory bodies in the US, UK, and EU have established stringent guidelines that necessitate thorough vendor oversight and contract…

Read More “Vendor Oversight and Contracts for Technology-Heavy Regulatory Expectations for DCTs” »